{"disease":{"id":"saliva","name":"saliva"},"drugs":{"marketed":[{"drug_id":"trastuzumab","indication_name":"HER2-positive salivary gland tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Herceptin","generic_name":"trastuzumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"HER2 receptor, subdomain IV","drug_class":"Antibody-drug conjugate (ADC)","quality_score":10,"revenue":"2900","mechanism":"HER2-targeted antibody-drug conjugate delivering microtubule inhibitor DM1 to HER2-overexpressing cells."},{"drug_id":"glycopyrronium-bromide","indication_name":"Excessive salivation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cuvposa","generic_name":"GLYCOPYRRONIUM BROMIDE","company_name":"Shionogi","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Anticholinergic","quality_score":62,"revenue":null,"mechanism":"Cuvposa works by blocking the action of a chemical called acetylcholine, which stimulates the muscarinic receptors in the body."},{"drug_id":"glycopyrrolate","indication_name":"Excessive salivation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Glycopyrrolate","company_name":"Yonsei University","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"trastuzumab-dkst","indication_name":"HER2-positive salivary gland tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"OGIVRI","generic_name":"TRASTUZUMAB-DKST","company_name":"MYLAN GMBH","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"HER2/neu Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"trazimera","indication_name":"HER2-positive salivary gland tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Herceptin","generic_name":"Trastuzumab-Qyyp","company_name":"Roche","drug_phase":"marketed","molecular_target":"HER2 (c-erbB2) proto-oncogene transmembrane receptor protein","drug_class":"HER2/neu receptor antagonist monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Trastuzumab inhibits proliferation of HER2-overexpressing tumor cells and mediates antibody-dependent cellular cytotoxicity."},{"drug_id":"herceptin","indication_name":"HER2-positive salivary gland tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Herceptin","company_name":"National Cancer Institute (NCI)","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"trastuzumab-herceptin","indication_name":"HER2-positive salivary gland tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trastuzumab (Herceptin)","generic_name":"trastuzumab-herceptin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"hyoscyamine","indication_name":"Excessive salivation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(-)-Atropine","generic_name":"Hyoscyamine","company_name":"University of Kansas Medical Center","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M4","drug_class":"hyoscyamine","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"sialanar","indication_name":"Excessive salivation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Sialanar","company_name":"Proveca Pharma Limited","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":9,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05483374","title":"The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers","phase":"","overall_status":"RECRUITING","enrollment_count":13600,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT07072143","title":"An International Study on Pediatric Patients With Rare Tumors.","phase":"","overall_status":"RECRUITING","enrollment_count":6250,"lead_sponsor_name":"Azienda Ospedaliera di Padova","has_results":false},{"nct_id":"NCT00001196","title":"Evaluation of Salivary Gland Dysfunction","phase":"","overall_status":"TERMINATED","enrollment_count":1740,"lead_sponsor_name":"National Institute of Dental and Craniofacial Research (NIDCR)","has_results":false},{"nct_id":"NCT02628067","title":"Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1609,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT02327884","title":"Characterization of Diseases With Salivary Gland Involvement","phase":"","overall_status":"RECRUITING","enrollment_count":1150,"lead_sponsor_name":"National Institute of Dental and Craniofacial Research (NIDCR)","has_results":false},{"nct_id":"NCT07122128","title":"EVALUATION OF SALIVA AS LIQUID BIOPSY FOR EARLY DETECTION OF ORAL CANCER IN PATIENTS WITH ORAL-SUBMUCOUS FIBROSIS (OSMF)","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Liaquat University of Medical & Health Sciences","has_results":false},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04140526","title":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":733,"lead_sponsor_name":"OncoC4, Inc.","has_results":false},{"nct_id":"NCT02091141","title":"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":673,"lead_sponsor_name":"Genentech, Inc.","has_results":true},{"nct_id":"NCT01365169","title":"Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients\"","phase":"NA","overall_status":"RECRUITING","enrollment_count":590,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT00001852","title":"Natural History of Salivary Gland Dysfunction and Sjogren's Syndrome","phase":"","overall_status":"COMPLETED","enrollment_count":560,"lead_sponsor_name":"National Institute of Dental and Craniofacial Research (NIDCR)","has_results":false},{"nct_id":"NCT02568267","title":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":534,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT04386551","title":"Detection of COVID-19 in Saliva Collection","phase":"","overall_status":"COMPLETED","enrollment_count":501,"lead_sponsor_name":"Centre Hospitalier Universitaire, Amiens","has_results":false},{"nct_id":"NCT03942380","title":"Cell-free Tumor DNA in Head and Neck Cancer Patients","phase":"NA","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Christian von Buchwald","has_results":false},{"nct_id":"NCT06356272","title":"Oropharynx (OPX) Biomarker Trial","phase":"","overall_status":"RECRUITING","enrollment_count":440,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT00588770","title":"Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":403,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06920472","title":"This Present Study Can be Used by Clinicians Who Treat Psychiatric Patients: Dentists Might Expect Xerogenic Side Effects of Specific Psychiatric Drugs Which Can Affect Dental Treatment, and the Results Can Help Psychiatrist to Choose the Less Xerogenic Psychiatric Medication","phase":"","overall_status":"COMPLETED","enrollment_count":361,"lead_sponsor_name":"Semmelweis University","has_results":false},{"nct_id":"NCT01425892","title":"The Pathogenesis and Natural History of Sjogren's Disease","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"National Institute of Dental and Craniofacial Research (NIDCR)","has_results":false},{"nct_id":"NCT06047236","title":"Immune Biomarker Study for Salivary Gland Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"University of Erlangen-Nürnberg Medical School","has_results":false},{"nct_id":"NCT03578900","title":"Quality of Life and Sjögren Syndrome","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":289,"lead_sponsor_name":"Grupo de Investigação em Bioquímica e Biologia Oral","has_results":false},{"nct_id":"NCT06091878","title":"Gene Expression Profiling in a Validation Cohort of Locally Advanced and Recurrent/Metastatic Salivary Gland Cancers","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":250,"lead_sponsor_name":"Royal Marsden NHS Foundation Trust","has_results":false},{"nct_id":"NCT05390294","title":"Survival With Patients Treated With Salivary Gland Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":250,"lead_sponsor_name":"Clinical Center of Vojvodina","has_results":false},{"nct_id":"NCT07293481","title":"Discovery and Validation of Periodontitis Biomarkers","phase":"","overall_status":"RECRUITING","enrollment_count":228,"lead_sponsor_name":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","has_results":false},{"nct_id":"NCT06393140","title":"The Study on the Mechanism of Radiotherapy-elicited Immune Response","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06695845","title":"A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":false},{"nct_id":"NCT07254039","title":"AI-Assisted Saliva Diagnostics Using an Electrochemical Sensor Platform for Periodontitis Detection (SALIENCE)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Ostergotland County Council, Sweden","has_results":false},{"nct_id":"NCT06343337","title":"The Effects of Pregnancy on Oral Health","phase":"NA","overall_status":"COMPLETED","enrollment_count":198,"lead_sponsor_name":"Muğla Sıtkı Koçman University","has_results":false},{"nct_id":"NCT05087706","title":"Exploratory Study of Molecular Profile-Associated Evidence Guided Precision Therapy for Salivary Gland Cancer（MAPS）","phase":"","overall_status":"UNKNOWN","enrollment_count":182,"lead_sponsor_name":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","has_results":false},{"nct_id":"NCT04352959","title":"COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses","phase":"NA","overall_status":"COMPLETED","enrollment_count":176,"lead_sponsor_name":"Claude Bernard University","has_results":false},{"nct_id":"NCT05075980","title":"Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":174,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT00001390","title":"Salivary Evaluation in Healthy Volunteers","phase":"","overall_status":"COMPLETED","enrollment_count":173,"lead_sponsor_name":"National Institute of Dental and Craniofacial Research (NIDCR)","has_results":false},{"nct_id":"NCT06578832","title":"Assessment of The Oral Health Status of Children With Chronic Kidney Disease","phase":"","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Marmara University","has_results":false},{"nct_id":"NCT04028479","title":"The Registry of Oncology Outcomes Associated With Testing and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Taproot Health","has_results":false},{"nct_id":"NCT06618209","title":"Assessment of Oral Health Status of Children With Primary Ciliary Dyskinesia","phase":"","overall_status":"COMPLETED","enrollment_count":160,"lead_sponsor_name":"Marmara University","has_results":false},{"nct_id":"NCT06354205","title":"Comparison of Salivary Procalcitonin (PCT) Levels and Serum PCT Levels","phase":"NA","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"Ege University","has_results":false},{"nct_id":"NCT04969835","title":"A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":158,"lead_sponsor_name":"Avacta Life Sciences Ltd","has_results":false},{"nct_id":"NCT03517488","title":"A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT01969578","title":"Androgen Deprivation Therapy in Advanced Salivary Gland Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":149,"lead_sponsor_name":"European Organisation for Research and Treatment of Cancer - EORTC","has_results":false},{"nct_id":"NCT05408845","title":"Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":146,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT05242991","title":"Effectiveness of Photobiomodulation Protocols in Radiation-induced Oral Side Effects in H&N Cancer Patients","phase":"NA","overall_status":"UNKNOWN","enrollment_count":132,"lead_sponsor_name":"Federal University of Rio Grande do Sul","has_results":false},{"nct_id":"NCT02245100","title":"Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":130,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","has_results":false},{"nct_id":"NCT06034782","title":"Diagnostic Accuracy of Fine Needle Aspiration in Patients With Salivary Gland Tumors.","phase":"","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"Aristotle University Of Thessaloniki","has_results":false},{"nct_id":"NCT04507646","title":"The Effectiveness of Auricular Acupuncture on Improving Secretion of Saliva Among Institutional Older Population","phase":"NA","overall_status":"COMPLETED","enrollment_count":124,"lead_sponsor_name":"Taipei Medical University","has_results":false},{"nct_id":"NCT06319118","title":"A Clinical Study of Dihydroergotine Mesylate Extended-release Tablets for the Treatment of Drooling in Parkinson's Disease.","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Second Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT05898373","title":"Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Peking Union Medical College","has_results":false},{"nct_id":"NCT07507578","title":"A Multi-omics Approach to Disclose Progression and Underlying Biology of Head and Neck Adenoid Cystic Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":114,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT06924372","title":"Application of Salivary Biomarkers in Risk Assessment for Oral Diseases in Children With Type 1 Diabetes","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":112,"lead_sponsor_name":"University of Novi Sad","has_results":false},{"nct_id":"NCT02776163","title":"Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland Carcinomas","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":107,"lead_sponsor_name":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","has_results":false},{"nct_id":"NCT06576856","title":"Salivary Markers in Periodontal Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":106,"lead_sponsor_name":"Midwestern University","has_results":false},{"nct_id":"NCT04639219","title":"A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":102,"lead_sponsor_name":"AstraZeneca","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}